Matthew Schipper retweeted
NEW: A novel tool predicts long-term risk of dying from #ProstateCancer, helping doctors interpret PSA results more accurately. Tested on over 200K men, it could help doctors tailor screening and treatment to individual risk and life expectancy. Read now: bit.ly/4pHyUwz @stensy @wandering_gu @UMichUrology #Cancer #CancerScreening
Matthew Schipper retweeted

U-M Epidemiology@umichepid12 Jun 2025
🇺🇸
United StatesConnected via United States App StoreAccount-level information, not a live location or per-post device.
Enhance your expertise in public health with our Summer Session in Epidemiology. Online from July 7-25, you'll gain skills in design and analysis of clinical trials from Dr. Matthew Schipper @StatMatt9 @umichsph
Matthew Schipper retweeted
Congratulations to Matt Schipper (@StatMatt9) for winning the @UMich Research Faculty Mentor Award. Matt has a tremendous record of supporting and training dozens of students, staff, trainees, and faculty, so this is very well-deserved! @UMichRadOnc @UMRogelCancer @MichRadOncRes
Matthew Schipper retweeted
A study from the @VAAnnArbor provides more data on the impact of lung cancer screening, this time evaluating the survival of a cohort of >2,000 screen-detected lung cancers. acsjournals.onlinelibrary.wi…
Matthew Schipper retweeted
It is with profound sadness that we mourn the passing of Felix Feng—an incredible father, husband, UCSF leader, pioneering scientist, entrepreneur, mentor, and cherished friend. Felix’s enduring kindness, brilliant mind, generous spirit, and transformative work in prostate cancer research have touched and saved countless lives. His legacy of compassion, innovation, and excellence will continue to inspire us all. My deepest condolences to Mary, Eric, & Emily during this heartbreaking time. May the One who brings Peace bring Peace to All.💔
Matthew Schipper retweeted
Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study Out on Lancet Oncology
This retrospective cohort study aimed to evaluate the effectiveness and safety of immune checkpoint inhibitors (ICIs) in Black patients, who were underrepresented in clinical trials leading to ICIs’ approval. Using data from the U.S. Veterans Health Administration, the study included 26,398 patients, of whom 18.7% were Black and 81.3% were White. Results showed that Black patients had a longer time to treatment discontinuation, similar time to next treatment, and slightly improved overall survival compared to White patients. Additionally, Black patients experienced significantly fewer immune-related adverse events, including lower risks of colitis and thyroid issues. These findings suggest that Black patients may have a more favorable therapeutic ratio for ICI treatment, though further investigation is needed to assess the generalizability of these results.
@StatMatt9
@garthstrohbehn
@DariaBrinzevich
@KamyaSankar
buff.ly/4fBgtpa
Matthew Schipper retweeted
Replying to @UMichRadOnc
@UMichRadOnc is hiring! We have positions in both GU and Breast and are looking for enthusiastic candidates to apply and join an amazing team of clinicians, physicists, and biologists! #GoBlue. #theteam @ARRO_org @ASTRO_org @ACRORadOnc
Matthew Schipper retweeted
Fantastic work, @MLE_Alger, on presenting your first PhD paper @eClinicalMed! rb.gy/7xumij
Appreciate the great collaboration with our brilliant multidisciplinary co-authors @Anna_Minchom @lee_1881 @StatMatt9.
Keep up the amazing work! 👏 @ICR_CTSU
Delighted to present my review on the current landscape of Patient-Reported Outcomes in early phase dose-finding trials at @SCTorg’s Annual Meeting this week! #SCT2024
📌 doi.org/10.1016/j.eclinm.202…
Matthew Schipper retweeted
🌟 Introducing the Weiser Center for Prostate Cancer 🌟
A new era in #prostatecancer care begins at University of Michigan. Our mission: innovation, compassion, and #patientcenteredcare. Discover how:
🔗weiserprostatecancer.org
youtube.com/watch?v=pX33Hj5P… 📽️
Matthew Schipper retweeted
Excited to share our work showing the first validation of surrogate endpoints in HPV+ oropharyngeal cancer! We show that LRPFS, DMFS, and PFS correlate with 5yr OS. Important for trial design in this evolving dx space @MierzwaMichelle @StatMatt9 @NRGonc
sciencedirect.com/science/ar…
Matthew Schipper retweeted
Currently in the midst of a productive meeting with the @MROQC1 consortium, focused on enhancing the quality of radiation treatment across Michigan. #lungcancer @UMichRadOnc @UMRogelCancer – at Ann Arbor, MI
Matthew Schipper retweeted

U-M Epidemiology@umichepid24 Apr 2023
🇺🇸
United StatesConnected via United States App StoreAccount-level information, not a live location or per-post device.
Meet our instructors for the Clinical Epidemiology Cluster! EPID 716: Clinical Epidemiology & Evidenced-Based Research being taught by Dr. Caroline Thompson and EPID 717: Design and Analysis of Clinical Trials is being taught by @StatMatt9. Learn more at: myumi.ch/G1bbn
Matthew Schipper retweeted
Four decades of clinical trials: 14.2 million life-years gained, at $326 per year medicalxpress.com/news/2022-…
Matthew Schipper retweeted
Matt Yglesias has left vox
In case folks are not following, we have a serious cultural problem 👇 with 2 issues
1. intolerance to debate ideas you do not agree with
2. inability to agree 75%, 65% or some fraction with another person
theatlantic.com/ideas/archiv…
Matthew Schipper retweeted
It is an honor to have an editorial written by @LGM_Biostats and @brian_rini to accompany our latest paper on the timing of cancer treatment in COVID19 times in @JAMAOnc. ja.ma/37Rwret
Which patients with cancer can tolerate a treatment delay during #COVID19 pandemic without a substantial impact on their cancer outcomes? Hartman etal have created a model to help decide. Read @brian_rini and my editorial.ja.ma/34DdgD9 via @JAMAOnc part of @JAMANetwork
Matthew Schipper retweeted
(1/n) The Pfizer SARS-Cov-2 vaccine trial has 4 interim analyses. Each interim has a set number of events and certain splits result in declaring efficacy or futility. If they were to announce “the trial is continuing after interim X”, what might we learn?
pfe-pfizercom-d8-prod.s3.ama…
Matthew Schipper retweeted
Very cool! Great talk by @drmattmcfarlane revealing a new web-based prediction tool for grade 2 and 3 radiation pneumonitis! (Based on @MROQC1 data)
Check it out: ppa.mroqc.org/
#ASTRO20 #lcsm @ASTRO_org @ARRO_org
Matthew Schipper retweeted
My mentors are amazing individuals but this is absolutely hilarious !!! 😂 #womeninmedicine #medtwitter #meded #oncmeded
Matthew Schipper retweeted
That “not a real doctor” thing . . . It’s kind of silly for people to think that going to medical school for a few years will give you the skills necessary to be able to evaluate research claims in medicine or anything else. statmodeling.stat.columbia.e…
Matthew Schipper retweeted
Great tips in this @nature article on how to give a good talk. Tell a story about your work & why the findings matter. Be kind to the audience by giving a big picture, key content, simplifying and enlarging figures & tables. Convey a small # of main takeaways simply & clearly
Scientific presentations are too often confusing, boring and overstuffed. Here are some suggestions that could make your next conference talk or seminar more enjoyable, engaging and effective. go.nature.com/3hkLdvW

































